Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
44results about How to "Developmental delay" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Individualized vaccines for cancer
ActiveUS20140178438A1Reduces steric hindranceImprove translationVaccinesPharmaceutical delivery mechanismPrimary tumorTumour metastasis
The present invention relates to the provision of vaccines which are specific for a patient's tumor and are potentially useful for immunotherapy of the primary tumor as well as tumor metastases. In one aspect, the present invention relates to a method for providing an individualized cancer vaccine comprising the steps: (a) identifying cancer specific somatic mutations in a tumor specimen of a cancer patient to provide a cancer mutation signature of the patient; and (b) providing a vaccine featuring the cancer mutation signature obtained in step (a). In a further aspect, the present invention relates to vaccines which are obtainable by said method.
Owner:TRANSLATIONALE ONKOLOGIE AN DER UNIVSMEDIZIN DER JOHANNES GUTENBERG UNIV MAINZ GGMBH +1
Antigen-Specific T Cell Receptors and T Cell Epitopes
ActiveUS20130273647A1Reliable detectionMeasureVirusesPeptide/protein ingredientsMHC restrictionCellular receptor
The present invention relates to efficient methods for providing antigen-specific lymphoid cells. These lymphoid cells may be used to provide antigen specific T cell receptors having a defined MHC restriction and to identify immunologically relevant T cell epitopes. Furthermore, the present invention relates to antigen-specific T cell receptors and T cell epitopes and their use in immunotherapy.
Owner:TRON TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITATSMEDIZIN DER JOHANNES GUTENBERG UNIVERS +1
Predicting immunogenicity of t cell epitopes
ActiveUS20160125129A1Minimizing chanceDevelopmental delayMicrobiological testing/measurementVaccinesOncologyImmunogenicity
The present invention relates to methods for predicting T cell epitopes. In particular, the present invention relates to methods for predicting whether modifications in peptides or polypeptides such as tumor-associated neoantigens are immunogenic or not. The methods of the invention are useful, in particular, for the provision of vaccines which are specific for a patient's tumor and, thus, in the context of personalized cancer vaccines.
Owner:BIONTECH SE +1
Individualized vaccines for cancer
ActiveUS10738355B2Reduces steric hindranceImprove translationVaccinesPharmaceutical delivery mechanismPrimary tumorTumour metastasis
The present invention relates to the provision of vaccines which are specific for a patient's tumor and are potentially useful for immunotherapy of the primary tumor as well as tumor metastases. In one aspect, the present invention relates to a method for providing an individualized cancer vaccine comprising the steps: (a) identifying cancer specific somatic mutations in a tumor specimen of a cancer patient to provide a cancer mutation signature of the patient; and (b) providing a vaccine featuring the cancer mutation signature obtained in step (a). In a further aspect, the present invention relates to vaccines which are obtainable by said method.
Owner:TRANSLATIONALE ONKOLOGIE AN DER UNIVSMEDIZIN DER JOHANNES GUTENBERG UNIV MAINZ GGMBH +1
Cancer therapy using cldn6 target-directed antibodies in vivo
ActiveUS20130183305A1Improve survivalReduces tumor cell growthAnimal cellsCell receptors/surface-antigens/surface-determinantsAntibodyWilms tumour
The invention relates to the treatment and / or prevention of tumor diseases associated with cells expressing CLD-N6, in particular cancer and cancer metastasis using antibodies which bind to CLDN6. The present application demonstrates that the binding of antibodies to CLDN6 on the surface of tumor cells is sufficient to inhibit growth of the tumor and to prolong survival and extend the lifespan of tumor patients. Furthermore, binding of antibodies to CLDN6 is efficient in inhibiting growth of CLDN6 positive germ cell tumors such as teratocarcinomas or embryonal carcinomas, in particular germ cell tumors of the testis.
Owner:JOHANNES GUTENBERG UNIV +1
Individualized vaccines for cancer
ActiveUS20160058853A1Minimizing chanceDevelopmental delayCancer antigen ingredientsWhole-cell/virus/DNA/RNA ingredientsCancer cellTreatment targets
The present invention relates to a patient-specific tumor treatment targeting individual expression patterns of tumor antigens, in particular shared tumor antigens, and individual tumor mutations. In one aspect, the present invention relates to a method for preventing or treating cancer in a patient comprising the steps of: (i) inducing a first immune response against one or more tumor antigens in the patient, and (ii) inducing a second immune response against one or more tumor antigens in the patient wherein the second immune response is specific for cancer specific somatic mutations present in cancer cells of the patient.
Owner:TRON TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITATSMEDIZIN DER JOHANNES GUTENBERG UNIVERS
Use of 15-Lipoxygenase Inhibitors for Treating Obesity
ActiveUS20090060905A1Preserve immunogenicityImprove the situationHalogenated hydrocarbon active ingredientsBiocideObesityVisceral Obesity
The invention concerns the treatment of obesity, in particular abdominal visceral obesity. More specifically, the invention concerns the use of selective 15-lipoxygenase (LO) inhibitors for preparing medicines useful in the treatment of obesity, or at least abdominal visceral obesity, and / or its consequences.
Owner:GENFIT SA
Methods of suppressing hepatitis virus infection using immunomodulatory polynucleotide sequences
InactiveUS7727712B2Reduce incidenceReduce severityOrganic active ingredientsMicrobiological testing/measurementAntigenNucleotide
Methods are provided for the treatment of hepatitis B virus (HBV) and hepatitis C virus (HCV) infections. A polynucleotide comprising an immunostimulatory sequence is administered to a individual who has been exposed to or infected by HBV and / or HCV. The polynucleotide is not administered with a HCV or HBV antigen. Administration of the polynucleotide results in amelioration of symptoms of HBV and / or HCV infection.
Owner:DYNAVAX TECH CORP
Garden stuff bean curd and technique of preparing the same
InactiveCN101411431AHigh quality contentHigh nutritional valueCheese manufactureFood preparationSoybean oilFruits vegetables
The invention relates to fruit-vegetable bean curd with abundant nutrition and a preparation process thereof. The fruit-vegetable bean curd is prepared from the following raw materials in weight percentage: the ratio of soybean to soybean oil to fruit-vegetable is 100-300 to 60-70 to 10-50. The fruit-vegetable bean curd has fresh and delicious taste, smooth and soft mouthfeel, lustrousness, attractive appearance, simple and uncomplicated raw materials, available material source, simple processing and preparing process, and short preparation flow, and is convenient to grasp and exert, has no any risk in production, transportation or storage, and has wide market prospect.
Owner:刘凤侠
Tumor antigens for determining cancer therapy
ActiveUS20160175414A1Reduce riskMinimizing chancePeptide librariesTumor rejection antigen precursorsCancer therapyOncology
The present invention relates to the treatment of cancer, in particular breast cancer, particularly triple-negative breast cancer. More particularly, the invention concerns methods and means for cancer treatment involving a specific set of tumor antigens.
Owner:TRON GGMBH +1
Immunotoxin derived from a recombinant human autoantibody and method of using thereof
ActiveUS20060013809A1Preventing Myasthenia GravisInduce immune toleranceHybrid immunoglobulinsAntibody ingredientsPseudomonas aeruginosa exotoxin ACDNA library
The invention is directed to an immunotoxin directed at fetal AchR, wherein the immunotoxin may comprises a human Fab fragment based on a human autoantibody or human combinatorial cDNA library and may be a pseudomonas exotoxin A-based single chain Fv IT (35-scFV-ETA). The invention is further directed to method of treating a patient with soft tissue tumour comprising the step of exposing the patient to the immunotoxin of the invention.
Owner:ISIS INNOVATION LTD
Methods of treating obesity or diabetes using NT-4/5
InactiveUS20050209148A1Lower Level RequirementsReduce weightPeptide/protein ingredientsMetabolism disorderDiseaseMetabolic syndrome
The invention concerns methods for treating obesity, non-insulin dependent diabetes mellitus, metabolic syndrome, and other related diseases by administering an NT-4 / 5 polypeptide. The invention also concerns compositions and kits comprising an NT-4 / 5 polypeptide.
Owner:RINAT NEUROSCI CORP
Compositions and methods for treatment and prevention of gastrointestinal disorders
ActiveUS20070123499A1Clinical severity of was improvedLoss preventionBiocidePharmaceutical delivery mechanismAngiotensin-converting enzymeInflammatory Bowel Diseases
The present invention provides compositions and methods for treating and preventing inflammatory bowel disease and other gastrointestinal disorders (e.g., mucositis, radiation induced enteritis, and short bowel syndrome). In particular, the present invention provides methods of treating and preventing symptoms of inflammatory bowel disease and other gastrointestinal disorders using compositions comprising an angiotensin converting enzyme (ACE) inhibitor and polyethylene glycol.
Owner:RGT UNIV OF MICHIGAN
Claudin-18.2-specific immunoreceptors and t cell epitopes
ActiveUS20180282389A1Minimize adverse effectsMinimizing chancePolypeptide with localisation/targeting motifImmunoglobulin superfamilyAntigen receptorsSpecific immunity
Owner:BIONTECH CELL & GENE THERAPIES +1
Methods for treating taxol-induced gut disorder
InactiveUS20070014786A1Avoid developmentHigh recovery rateDigestive systemImmunoglobulins against cell receptors/antigens/surface-determinantsAntibodyPaclitaxel
This invention relates to the field of taxol-induced gut disorder. More specifically, the invention relates to methods of treating taxol-induced gut disorder comprising administration of agonist anti-trkC antibody for the treatment, prevention, and / or amelioration of a symptom of taxol-induced gut disorder.
Owner:RINAT NEUROSCI CORP
Fused pyrimidine compounds and use thereof
InactiveUS20140179668A1Prevent delayDevelopmental delayBiocideOrganic active ingredientsPyrimidineCancer
Fused pyrimidine compounds as kinase inhibitors, such as multi-kinase inhibitors, are provided. Fused pyrimidine compounds as IGF-IR inhibitors are provided. The compounds may be used in a method of treating cancer. Pharmaceutical compositions containing a fused pyrimidine compound and a pharmaceutically acceptable carrier are also provided, as are kits containing a fused pyrimidine compound or salt thereof and instructions for use, e.g., in a method of treating cancer.
Owner:MEDIVATION TECH INC
Myosin 15 promoters and uses thereof
PendingUS20210388045A1Affecting its functionReduce developmentVectorsPeptide/protein ingredientsHL - Hearing lossMyosin
The disclosure provides polynucleotides containing regions of the Myosin 15 (Myo15) promoter, as well as vectors containing the same, that can be used to promote expression of a transgene specifically in hair cells. The polynucleotides described herein may be operably linked to a transgene, such as a transgene encoding a therapeutic protein, so as to promote hair cell-specific expression of the transgene. The polynucleotides described herein may be operably linked to a therapeutic transgene and used for the treatment of subjects having or at risk of developing hearing loss or vestibular dysfunction.
Owner:DECIBEL THERAPEUTICS INC +1
Predicting immunogenicity of T cell epitopes
ActiveUS11222711B2Minimizing chanceDevelopmental delayMicrobiological testing/measurementVaccinesOncologyImmunogenicity
The present invention relates to methods for predicting T cell epitopes. In particular, the present invention relates to methods for predicting whether modifications in peptides or polypeptides such as tumor-associated neoantigens are immunogenic or not. The methods of the invention are useful, in particular, for the provision of vaccines which are specific for a patient's tumor and, thus, in the context of personalized cancer vaccines.
Owner:BIONTECH SE +1
Individualized vaccines for cancer
ActiveUS10155031B2Improve binding stabilityImproving immunogenicityCancer antigen ingredientsWhole-cell/virus/DNA/RNA ingredientsCancer cellTreatment targets
The present invention relates to a patient-specific tumor treatment targeting individual expression patterns of tumor antigens, in particular shared tumor antigens, and individual tumor mutations. In one aspect, the present invention relates to a method for preventing or treating cancer in a patient comprising the steps of: (i) inducing a first immune response against one or more tumor antigens in the patient, and (ii) inducing a second immune response against one or more tumor antigens in the patient wherein the second immune response is specific for cancer specific somatic mutations present in cancer cells of the patient.
Owner:TRON TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITAETSMEDIZIN DER JOHANNES GUTENBERG UNIV MAINZ GEMEINNUETZIGE GMBH
Immunotoxin derived from a recombinant human autoantibody and method of using thereof
ActiveUS8114969B2Developmental delayPreventing Myasthenia GravisAntibody ingredientsImmunoglobulinsCDNA libraryPseudomonas aeruginosa exotoxin A
The invention is directed to an immunotoxin directed at fetal AchR, wherein the immunotoxin may comprises a human Fab fragment based on a human autoantibody or human combinatorial CDNA library and may be a pseudomonas exotoxin A-based single chain Fv IT (35-scFV-ETA). The invention is further directed to method of treating a patient with soft tissue tumor comprising the step of exposing the patient to the immunotoxin of the invention.
Owner:ISIS INNOVATION LTD
Antibodies useful in cancer diagnosis
ActiveUS20200199221A1Reduce riskEasy to prepareBiological material analysisMicroorganism based processesEpitopeCancer cell
Owner:ASTELLAS PHARMA INC +1
Claudin-6-specific immunoreceptors and T cell epitopes
ActiveUS10370423B2Minimize adverse effectsMinimizing chanceTumor rejection antigen precursorsPeptide/protein ingredientsAntigen receptorsImmunotherapy
Owner:BIONTECH CELL & GENE THERAPIES +2
Techniques for analyzing non-verbal markers of conditions using electrophysiological data
InactiveUS20190175049A1Delay in developing language skillDevelopmental delayElectroencephalographyKernel methodsElectricityMedicine
Embodiments related to analyzing brain activity of a subject to identify signs associated with binocular rivalry. Sensed electrical activity of a subject's brain is received over a time period while the subject is exposed to a visual stimulus. The sensed electrical activity comprises a first frequency band associated with a first frequency of a first image presented to the subject's left eye, a second frequency band associated with a second frequency of a second image presented to the subject's right eye. A set of events in the time period is determined based on the frequency bands, wherein an event is associated with a change from a previous perceptual event to a new perceptual event. A metric for the subject is determined based on the set of events. The metric is analyzed to determine whether the subject exhibits signs associated with a condition that is associated with binocular rivalry.
Owner:MASSACHUSETTS INST OF TECH
Individualized Vaccines for Cancer
ActiveUS20190083593A1Minimizing chanceDevelopmental delayCancer antigen ingredientsWhole-cell/virus/DNA/RNA ingredientsCancer cellOncology
Owner:TRON TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITAETSMEDIZIN DER JOHANNES GUTENBERG UNIV MAINZ GEMEINNUETZIGE GMBH +1
Use of 15-lipoxygenase inhibitors for treating obesity
ActiveUS8048900B2Preserve immunogenicityImprove the situationBiocideHalogenated hydrocarbon active ingredientsObesityVisceral Obesity
The invention concerns the treatment of obesity, in particular abdominal visceral obesity. More specifically, the invention concerns the use of selective 15-lipoxygenase (LO) inhibitors for preparing medicines useful in the treatment of obesity, or at least abdominal visceral obesity, and / or its consequences.
Owner:GENFIT SA
Tumor antigens for determining cancer therapy
ActiveUS10188712B2Reduce riskMinimizing chanceTumor rejection antigen precursorsMicrobiological testing/measurementOncologyTumor antigen
Owner:TRON GGMBH +1
Programmed cell death and Ich-3
InactiveUS20030049709A1Delayed follicle activationDevelopmental delayOrganic active ingredientsBiocidePhysiologyTransgenesis
This invention relates to modulation of programmed cell death. It also relates to transgenic non-human animals comprising a disrupted Ich-3 gene and methods of making these animals. The Ich-3 mutant animals exhibit resistance to septic shock and defects in folliculogenesis. This invention also relates to methods of using the transgenic animals to screen for compounds to treat septic shock and defective folliculogenesis. Moreover, this invention also relates to methods of treating septic shock in normal individuals by inhibiting ICH-3.
Owner:YUAN JUNYING +3
Aav1 vectors and uses thereof for treatment of otic indications
PendingUS20210355504A1Strong expressionSuperior tropismSenses disorderPharmaceutical delivery mechanismVestibular dysfunctionElectrophonic hearing
The invention provides AAV1 vectors that can be used to transduce multiple inner ear cell types and their use for treatment of hearing loss, deafness, tinnitus, and vestibular dysfunction.
Owner:DECIBEL THERAPEUTICS INC
Predicting T cell epitopes useful for vaccination
ActiveUS11156617B2Minimizing chanceDevelopmental delayCompound screeningApoptosis detectionVaccinationTGE VACCINE
Owner:BIONTECH SE
Predicting immunogenicity of t cell epitopes
PendingUS20220093209A1Minimizing chanceDevelopmental delayMicrobiological testing/measurementVaccinesOncologyImmunogenicity
The present invention relates to methods for predicting T cell epitopes. In particular, the present invention relates to methods for predicting whether modifications in peptides or polypeptides such as tumor-associated neoantigens are immunogenic or not. The methods of the invention are useful, in particular, for the provision of vaccines which are specific for a patient's tumor and thus, in the context of personalized cancer vaccines.
Owner:BIONTECH SE
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com